其 他 安 全 警 示
|
| |
| Canada: Summary Safety Review: Amoxicillin-containing products: Assessing the potential risks of Aseptic meningitis (English only) |
| |
Health Canada reviewed the potential risk of aseptic meningitis in patients treated with amoxicillin-containing products. The safety review was triggered by case reports published in the literature in the past 3 years concerning this risk.
Health Canada reviewed the available information from searches of the Canada Vigilance database, international databases, and published literature and concluded that there may be a link between the use of amoxicillin-containing products and the risk of aseptic meningitis. Health Canada will work with the manufacturers to include the risk of aseptic meningitis in the Canadian Product Monographs for amoxicillin-containing products that do not already contain this safety information.
Please refer to the following website in Health Canada for details:
http://hpr-rps.hres.ca/../summary-safety-review-detail.php?lang=en&linkID=SSR00276
In Hong Kong, there are 180 registered pharmaceutical products for human use containing amoxicillin and are prescription-only medicines. So far, the Department of Health (DH) has received 28 cases of adverse drug reaction related to amoxicillin, but these cases are not related to aseptic meningitis. In light of the above Health Canada’s announcement, letters to inform local healthcare professionals will be issued. The DH will remain vigilant on safety update of the drug issued by other overseas drug regulatory authorities.
Ends/ Saturday, Dec 11, 2021
Issued at HKT 13:00
|
| |
|
